Drugs / 188Re-SSS Lipiodol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01126463 | May 2010 → Aug 2019 | hepatocellular carcinoma | Center Eugene Marquis | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05797870 | Feb 2024 → Jan 2025 | hepatocellular carcinoma | Center Eugene Marquis | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 188Re-SSS lipiodol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05797870 ↗ |
| Modality | Other / unclassified | “188Re-SSS lipiodol, a new radioactive labeled stable complex has been developed.” NCT01126463 ↗ |
| Route | Other | “Hepatic Intra-Arterial Administration of radio-active lipiodol.” NCT01126463 ↗ |